logo
logo

Immunitas Therapeutics, Inc. announced it raised $29.1 Million in an initial filing from an offering of $57.7 Million

Immunitas Therapeutics, Inc. announced it raised $29.1 Million in an initial filing from an offering of $57.7 Million

08/24/21, 6:44 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgwaltham
Money raised
$29.1 million
Industry
biotechnology

Company Info

Company
Immunitas Therapeutics, Inc.
Location
830 winter street, 2nd floor
waltham, massachusetts, united states
Additional Info
Immunitas is an immuno-oncology therapeutics company advancing multiple programs to the clinic. Immunitas’ programs are derived from a cross-functional, highly integrated, single cell genomics platform that enables rapid target identification and validation in parallel with antibody discovery and engineering. IMT-009, a first-in-class T & NK cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. The company was founded with leading scientists from Dana Farber, MGH, the Broad, and MIT. In 2019, Immunitas raised a $39M Series A from a strong syndicate of investors including the Longwood Fund, Hillhouse, NVF, Leaps by Bayer, and M Ventures.

Related People